World Journal of Hepatology最新文献

{"title":"Splenectomy and risk of hepatocellular carcinoma.","authors":"Da-Qing Li, Zhen-Yi Lin, Jian-Guo Wang, Rong-Qian Wu, Yu Zhang, Zhao-Qing Du","doi":"10.4254/wjh.v17.i7.107603","DOIUrl":"10.4254/wjh.v17.i7.107603","url":null,"abstract":"<p><p>Hypersplenism is a common complication of cirrhosis that is associated with significant impairment to patients' life quality. Splenectomy is often employed in clinical settings as a treatment for hypersplenism. While splenectomy is carried out for the purposes of alleviating hypersplenism-related adverse outcomes like thrombocytopenia or anaemia, studies have suggested alterations in the immune status, hemodynamics, and intestinal microbiota of patients following splenectomy, which may potentially influence the onset and progression of hepatocellular carcinoma (HCC). Additionally, patients have been found to face new health risks post-splenectomy, including infections and thrombosis, which could adversely impact their overall health and potentially increase the risk of HCC. Despite these findings, there is currently no consensus on whether splenectomy affects the risk of postoperative HCC in cirrhotic patients. This review synthesizes the pertinent literature on the incidence of HCC following splenectomy, with an emphasis on current evidence related to its physiology, pathophysiology, and epidemiology. Concepts such as immune status, hemodynamics changes, and intestinal microbiota in post-splenectomy patients are explored, in hopes that it can inform more individualized treatment approaches for patients.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107603"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular tumor boards in pancreatic cancer with liver metastasis: A case report.","authors":"Yan Yan, Zhi-Zhong Ren, Wen-Ya Wang, Jing Tang, Yue-Wei Zhang","doi":"10.4254/wjh.v17.i7.106993","DOIUrl":"10.4254/wjh.v17.i7.106993","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer has limited treatment options and poor prognosis owing to late diagnosis and aggressive biology. Current therapies include surgery, chemotherapy, and radiation; however, the outcomes remain suboptimal. Molecular tumor boards (MTB) enhance personalized treatment by analyzing genomic data to identify targetable mutations and recommend precise therapies.</p><p><strong>Case summary: </strong>A 45-year-old male presented with jaundice in December 2022. Initial investigations revealed a pancreatic head mass and liver metastases; a liver biopsy confirmed moderately differentiated adenocarcinoma. The patient received multimodal therapies, including gemcitabine, albumin-bound paclitaxel, nimotuzumab, and proton radiotherapy, which initially resulted in significant shrinkage of the pancreatic lesion and a reduction in liver metastases. However, the disease eventually progressed, prompting further evaluation at our MTB clinic. Genetic testing revealed a homologous recombination deficiency (HRD) score of 58 (HRD-positive) and a pathogenic BRCA2 mutation (p.T3033fs), suggesting sensitivity to PARP inhibitors and platinum-based therapies. Based on these findings, the patient was administered olaparib, which, combined with immunotherapy (tislelizumab, atezolizumab) and hepatic arterial infusion chemotherapy (5-fluorouracil + leucovorin + oxaliplatin regimen), led to further stabilization and partial reduction of liver metastases. This case underscores the positive role of the MTB model in interpreting genetic profiles and guiding personalized treatment strategies for such patients.</p><p><strong>Conclusion: </strong>The patient's clinical course highlights the potential of MTB in providing significant benefits for advanced pancreatic cancer with liver metastases.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106993"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver stiffness measurements in patients with metabolic dysfunction-associated steatotic liver disease: Updates on the method effectiveness and perspectives.","authors":"Olga Sukocheva, Tsai-Wing Ow, Damian Harding, Marc Le Mire, Edmund Tse","doi":"10.4254/wjh.v17.i7.106675","DOIUrl":"10.4254/wjh.v17.i7.106675","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most widespread chronic liver disease signified by serious life-threatening conditions. The prevalence of MASLD increases along the growing prevalence in obesity and metabolic syndrome. To minimize costs and complications, non-invasive diagnostic tools, including transient elastography (TE), were introduced for assessment of MASLD. TE measures liver stiffness (LS), a clinical marker for the diagnosis of liver fibrosis and cirrhosis. LS measurements are based on ultrasound wave imaging and quantification. Vibration-controlled TE, including FibroScan^®, is commonly used TE methods which can accurately identify the degree of liver fibrosis and cirrhosis progression. TE was reported to predict the progression towards hepatocellular carcinoma, portal hypertension, and varices. However, the accuracy of LS diagnostics alone in patients with MASLD remains controversial. TE measurements have several limitations, including inadequate precision due to focal liver lesions, cholestasis, inflammation, and other pathological and anatomical factors which can lead to the stiffness variability. Overestimations of TE readings were reported in obese patients with body mass index (BMI) over 30 kg/m², and older patients with ascites, diabetes, or hypertension. Not all MASLD patients have high BMI. The prevalence of obesity among MASLD patients varies worldwide, indicating the urgent need for comprehensive diagnostic tools. In patients with MASLD, improved diagnostic accuracy has been demonstrated by combining LS measurements with other blood test-based scores and simple clinical parameters (agile scores based on age, sex, platelet count, aminotransferases, and diabetes). This study reviews the limitations of TE-based diagnostics and discusses the combined scoring algorithm. In conclusion, the sequence of LS measurements along assessment of other important clinical markers is an effective, low-cost, reliable tool to identify and monitor fibrosis progression in MASLD.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106675"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management.","authors":"Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Ajib Zaim Alamsyah, Ni Luh Putu Yunia Dewi, Ni Nyoman Gita Kharisma Dewi, I Ketut Mariadi, Dwijo Anargha Sindhughosa","doi":"10.4254/wjh.v17.i7.106810","DOIUrl":"10.4254/wjh.v17.i7.106810","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC), a primary malignancy of the liver and leading cause of cancer-related mortality worldwide, poses substantial therapeutic challenges, particularly in advanced and unresectable stages. Immune checkpoint inhibitors (ICIs) have emerged as critical therapeutic agents, targeting immune checkpoint pathways to restore antitumor immune responses. Combinations such as atezolizumab (anti-programmed cell death ligand 1 with bevacizumab (anti-vascular endothelial growth factor), as well as antibodies directed against cytotoxic T-lymphocyte associated protein 4 and programmed cell death protein 1 (<i>e.g.</i>, ipilimumab and nivolumab), have demonstrated improved clinical outcome in selected patients. However, the overall efficacy of ICIs remains hindered by variable response rate and primary or acquired resistance. Recent evidence suggests that the gut microbiome plays a pivotal role in modulating host immune responses and may significantly influence the therapeutic efficacy of ICIs. Dysbiosis within the gut-liver axis has been implicated not only in pathogenesis and progression of HCC but also diminishing immunotherapy effectiveness. Emerging studies highlight the potential of microbiome-targeted interventions including dietary modulation, prebiotics, probiotics, and fecal microbiota transplantation to enhance ICIs responsiveness. This review explores the evolving interplay between the gut microbiota and immunotherapy in HCC, with a focus on microbiome-based strategies aimed at optimizing clinical outcomes.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106810"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of <i>Klebsiella pneumoniae</i> infections post-liver transplantation: Insights and future directions.","authors":"Jian Li, Wei Wang","doi":"10.4254/wjh.v17.i7.107213","DOIUrl":"10.4254/wjh.v17.i7.107213","url":null,"abstract":"<p><p><i>Klebsiella pneumoniae</i> infections (KPIs), particularly carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP), pose significant challenges in liver transplantation (LT) recipients, with high morbidity and mortality. Guo <i>et al</i>'s study highlights risk factors, such as elevated day-one alanine aminotransferase levels and prolonged catheterization, and identifies polymyxin B and ceftazidime/avibactam as effective treatments. However, limitations like the absence of pre-transplant colonization data and host-pathogen interaction insights highlight the need for enhanced strategies. Future directions should include routine CRKP colonization surveillance, immune and genomic profiling, and the development of novel therapeutics. By integrating these approaches, we can improve the prevention, diagnosis, and treatment of KPIs in LT patients.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107213"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune hepatitis with syncytial giant cells in chronic lymphocytic leukemia: A case report and literature review.","authors":"Marta Giacomelli, Simone Carotti, Federico Vozella, Federica Pagliei, Chiara Taffon, Andrea Baiocchini, Francesco Luigi Gambaro, Antonio Picardi, Umberto Vespasiani-Gentilucci, Giovanni Galati","doi":"10.4254/wjh.v17.i7.106253","DOIUrl":"10.4254/wjh.v17.i7.106253","url":null,"abstract":"<p><strong>Background: </strong>Hepatic manifestations in chronic lymphocytic leukemia (CLL) are common: Elevation of liver enzymes frequently occurs, and differential diagnosis is often challenging. Liver infiltration by leukemic cells, primary and secondary hepatic malignancies, drug-induced hepatotoxicity, immunological disorders, and infections have been reported. Nevertheless, syncytial giant cell hepatitis (GCH) as a manifestation of autoimmune hepatitis in patients with CLL is an extremely rare condition, currently reported only in anecdotal cases.</p><p><strong>Case summary: </strong>Here, we report the case of a 62-year-old Caucasian woman affected by CLL, who developed GCH with peculiar histopathological features. The patient was evaluated for abnormal liver test results. Liver histology revealed significant inflammatory lymphomononuclear infiltrates with a plasma cell component, widespread syncytial changes in the hepatocytes with gigantocellular features, hepatocyte rosettes, and the typical feature of emperipolesis, consistent with a diagnosis of GCH. The patient was treated with corticosteroids and mycophenolate mofetil, resulting in a complete biochemical response.</p><p><strong>Conclusion: </strong>Early histological diagnosis of GCH is crucial in patients with CLL, with mycophenolate mofetil representing a promising treatment option.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"106253"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver immunology: Biological role and clinical significance.","authors":"Stanislav Nikolaevich Kotlyarov","doi":"10.4254/wjh.v17.i7.107541","DOIUrl":"10.4254/wjh.v17.i7.107541","url":null,"abstract":"<p><p>Liver diseases are of growing interest to clinicians and researchers due to their high prevalence, difficulty in early diagnosis, and limited treatment options. The liver is an important organ at the intersection of many metabolic and immune pathways. To this end, it contains a large number of immune cells of both the innate and adaptive immune system that perform multiple functions, detecting and destroying pathogens that enter the body through the intestine, as well as recognizing endogenous antigens. Immune cells in the liver have a complex regulation that can be impaired in various diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD), liver cancer, and biliary diseases. A growing body of evidence reinforces the realization that not only impaired metabolism but also many immune mechanisms underlie MASLD. The liver has complex bilateral immune and metabolic links with the gut microbiota, and disruptions of these links underlie the development and progression of both gastrointestinal and other organ diseases. In this regard, acting on immune mechanisms is a promising therapeutic target for liver diseases.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"107541"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes.","authors":"Shivangini Duggal, Lakshmi Kattamuri, Shrilekha Sairam","doi":"10.4254/wjh.v17.i7.108051","DOIUrl":"10.4254/wjh.v17.i7.108051","url":null,"abstract":"<p><strong>Background: </strong>Elevated liver enzymes in rheumatoid arthritis (RA) are often attributed to multiple factors including disease activity and treatment-related adverse effects. Tumor necrosis factor inhibitors (TNFi) have shown mixed effects on liver function, with varying safety profiles among agents.</p><p><strong>Aim: </strong>To evaluate the hepatic safety of TNFi therapy-etanercept and adalimumab-in RA patients with elevated liver enzymes.</p><p><strong>Methods: </strong>A retrospective chart review was conducted for RA patients with elevated liver enzymes receiving TNFi at a single center between January 1, 2019, and September 30, 2024. Out of the patients screened, 9 met the inclusion criteria. Trends in liver enzymes, fibrosis-4 (FIB-4) score, and changes in the Child-Pugh class were analyzed at 1-year and 3-year follow-up periods.</p><p><strong>Results: </strong>Among 9 patients (4 on adalimumab, 5 on etanercept), the median age was 56 years [interquartile range (IQR): 49.5-64.5 years], 77.8% were female, and the median body mass index was 36.99 kg/m² (IQR: 30.95-43.43 kg/m²). Median baseline FIB-4 was 1.25 (IQR: 1.02-1.65), with no cirrhosis observed at baseline. Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels declined consistently, with significant reductions from baseline to 3 years (<i>P</i> = 0.003). FIB-4 scores also significantly decreased (<i>P</i> = 0.003), while albumin, bilirubin, and Child-Pugh class remained stable at the 3-year follow-up. At 3 years, 66.7% achieved RA remission (<i>P</i> = 0.03).</p><p><strong>Conclusion: </strong>TNFi therapy (adalimumab or etanercept) was associated with significant improvement in liver enzymes and FIB-4 without hepatic decompensation, supporting its safety in our cohort of RA patients with liver involvement. Larger prospective studies are warranted to further validate these findings.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 7","pages":"108051"},"PeriodicalIF":2.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study.","authors":"Ming-Huang Zhang, Ning Meng, Kang-Hui Zhang, Jun-Kang Yu, Chen-Hao Huang, Shu Yang, Ding-Yi Zhu","doi":"10.4254/wjh.v17.i6.108096","DOIUrl":"10.4254/wjh.v17.i6.108096","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated fatty liver disease (MASLD) is a chronic liver disease characterized by hepatocellular steatosis, which is closely related to metabolic syndrome, with annually increasing morbidity in recent years. Gynecomastia (GYN), an abnormal proliferation of breast tissue in males, is common in males with sex hormone imbalance. Currently, there is insufficient research on the morbidity of GYN and its correlation among MASLD patients.</p><p><strong>Aim: </strong>To investigate the prevalence of GYN and its associated clinical features in patients with MASLD and determine the prevalence of GYN in patients with MASLD and analyze the predictive effect of sex hormones on GYN using receiver operating characteristic (ROC) curves.</p><p><strong>Methods: </strong>A cross-sectional study was conducted in a tertiary care hospital. Among them, 997 patients met the inclusion criteria and underwent breast ultrasonography to determine the presence of GYN. Anthropometric data, laboratory test data [estradiol (E2), androgens, liver function, glucose, lipids, low-density lipoprotein, high-density lipoprotein, creatinine, and uric acid, <i>etc.</i>], as well as information on medical history, severity of fatty liver (mild, moderate, and severe), and duration of the disease were collected. Package for the Social Sciences version 27 and R software (version 4.3.1) were used for data analysis.</p><p><strong>Results: </strong>The prevalence of GYN increased with the severity of fatty liver (27.6% for mild, 33.5% for moderate, and 58% for severe, <i>P</i> < 0.001); compared with non-GYN patients, GYN patients were older (54.11 ± 9.71 years <i>vs</i> 47.89 ± 9.92 years, <i>P</i> < 0.001), with significantly higher E2 levels, higher estrogen to androgen ratio (<i>P</i> < 0.001) and significantly lower androgen levels (<i>P</i> < 0.001). In ROC curve analysis, the combined model of testosterone and E2 had a high diagnostic value in predicting GYN in MASLD patients, surpassing a single indicator.</p><p><strong>Conclusion: </strong>The presence of GYN may suggest more severe metabolic abnormalities in patients with MASLD. Therefore, early recognition of GYN may be crucial for early intervention in metabolic syndrome and endocrine abnormalities in patients with MASLD.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 6","pages":"108096"},"PeriodicalIF":2.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144554998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of Liver FibraChek Dx^©, a blood-based test for the non-invasive detection of liver cirrhosis and cancer.","authors":"Fernando Siguencia, Michitaka Matsuda, Vijay Pandyarajan, Sunao Tanaka, Steven M Smith, Catherine Bresee, Ekihiro Seki, Charles J Rosser, Hideki Furuya","doi":"10.4254/wjh.v17.i6.106481","DOIUrl":"10.4254/wjh.v17.i6.106481","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis, and cirrhosis are major risk factors for hepatocellular carcinoma (HCC), yet current blood-based diagnostic assays lack sufficient accuracy for routine clinical use. Identifying a non-invasive molecular signature that accurately detects liver disease could improve early diagnosis and monitoring. We hypothesized that the Liver FibraChek Dx^© serum assay could discriminate MASLD and HCC from healthy controls using a multiplex biomarker-based algorithm.</p><p><strong>Aim: </strong>To evaluate the diagnostic performance of the Liver FibraChek Dx^© assay for detecting MASLD and HCC.</p><p><strong>Methods: </strong>This was a prospective, single-center study conducted in a United States tertiary care setting. Serum samples were collected from 45 participants (14 MASLD, 19 HCC, 12 healthy controls) with liver histology confirmed by biopsy. The Liver FibraChek Dx^© algorithm integrates weighted values of aspartate aminotransferase, alanine aminotransferase, taurocholic acid, L-tyrosine, platelet count, and patient age to generate a risk score. Wilcoxon rank sum tests were used to assess associations with histologic diagnosis, and receiver operating characteristic (ROC) curves quantified diagnostic performance.</p><p><strong>Results: </strong>Liver FibraChek Dx^© risk scores were significantly elevated in MASLD and HCC compared to controls (median: 6.92 ± 3.86 <i>vs</i> 3.61 ± 1.67, <i>P</i> < 0.001). The area under the ROC curve was 0.890 (95%CI: 0.776-1.000) for distinguishing diseased from healthy individuals. Sensitivity was 93.9%, specificity 75.0%, positive predictive value 91.1%, negative predictive value 81.8%, and overall accuracy 88.9%.</p><p><strong>Conclusion: </strong>The Liver FibraChek Dx^© assay accurately detects liver disease and shows promise as a non-invasive tool for diagnosing and monitoring MASLD and HCC.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 6","pages":"106481"},"PeriodicalIF":2.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144554999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}